Skip to content
OpenCapital
Get started

Biohaven BHVN Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%
Enterprise value$2.26B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value?
Biohaven (BHVN) reported share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value of $10.9M in Q1 2026.
How has Biohaven's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value changed year-over-year?
Biohaven's share based compensation arrangement by share based payment award options vested and expected to vest exercisable aggregate intrinsic value decreased by 92.0% year-over-year, from $136.82M to $10.9M.